micro-community-banner
 
  • Saved
Clinical Status, Treatment, and Disease Burden of Generalised Myasthenia Gravis in the Asia-Pacific - PubMed

Clinical Status, Treatment, and Disease Burden of Generalised Myasthenia Gravis in the Asia-Pacific - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41131267/

Across the Asia-Pacific, most patients did not achieve pharmacological remission despite prescribed treatments, and experienced treatment-related AEs, indicating significant unmet clinical needs. It is suggested that corticosteroid overreliance in maintenance...

A cross-sectional real-world survey across six Asia-Pacific countries found high disease burden in gMG patients, with most not achieving remission and experiencing corticosteroid-related adverse events, underscoring unmet therapeutic needs.

  • Saved
Functional Neurological Disorder: Advancing Diagnosis and Care for a Complex Neuropsychiatric Condition.

Functional neurological disorder (FND) is a disabling neuropsychiatric condition characterized by involuntary motor, sensory, or cognitive symptoms that are not explained by identifiable structural pathology. Once considered purely psychogenic, FND is now increasingly understood as a condition involving abnormal brain network connectivity and shaped by biopsychosocial factors.

Highlights:

  • FND is the second most common diagnosis in outpatient neurology, disproportionately affecting women and often emerging in early adulthood.
  • Neuroimaging studies reveal altered connectivity in circuits governing emotion, motor control, and self-agency, supporting FND as a genuine brain-based disorder.
  • Symptoms may include functional tremors, gait impairment, non-dermatomal sensory changes, and cognitive difficulties that do not align with classical neurological patterns.
  • Diagnosis increasingly focuses on “positive signs” of internal inconsistency and incongruence during neurologic examination, rather than exclusion of other diseases.
  • Optimal management requires a multidisciplinary approach—including neurology, psychiatry, psychology, and rehabilitation medicine.
  • Emerging predictive imaging techniques may enable future personalization of treatment strategies.

What sets this study apart:

This review underscores the evolution in how FND is diagnosed and treated—shifting from misdiagnosis and stigma toward evidence-based, multidisciplinary care. It highlights the need for early recognition, tailored interventions, and the continued development of objective diagnostic tools.

Limitations:

Challenges remain, including diagnostic uncertainty, persistent stigma, and the absence of standardized imaging protocols or individualized treatment pathways based on neurobiological profiles.

What role could predictive imaging play in guiding individualized treatment plans for FND?

  • Saved
Summary of Immunoglobulin National Society National Conference

The Immunoglobulin National Society (IgNS) National Conference is considered the premier annual event for clinicians, business professionals, and industry in the Ig therapy and biologics space. Attendees have access to preclinical and clinical studies, peer-to-peer collaboration, and professional development.

Above please find our postconference wrap-up report with summaries of research and presentations that caught our eye at the meeting.

  • Saved
American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) is hosting its annual meeting in San Francisco from Oct. 29 to Nov. 1, 2025. Physicians, technologists, advanced practice providers, and other health care professionals are invited to learn about the latest in neuromuscular (NM), musculoskeletal (MSK), electrodiagnostic (EDX), and NM ultrasound (NMUS).

Click above to access highlights at the upcoming conference.

  • Saved
Novel treatments for myasthenia gravis - PubMed

Novel treatments for myasthenia gravis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41101819/

Advances in immunology over the last several years have provided insights into the pathophysiology of autoimmune diseases such as generalized myasthenia gravis (gMG). This has translated into the development of...

This review discusses recent advances in gMG therapy, including complement C5 inhibitors and FcRn antagonists, and highlights emerging B-cell, chimeric antigen, and immune-tolerizing strategies reshaping individualized disease management.